An Analysis of the Bangladeshi Pharmaceutical Industry after LDC Graduation: Prospects and Challenges
DOI:
https://doi.org/10.52731/lbds.003.153Keywords:
IPRs, LDC, Pharmaceutical Industry, Bangladesh, WTO/TRIPSAbstract
Unusually as a least developed country (LDC), Bangladesh has a strong pharmaceutical industry. The country successfully developed its pharmaceutical industry due to two national drug policies (NDPs), NDP 1982 and NDP 2005, and the intellectual property waiver offered by TRIPS for LDCs. This study first analyzed the roles of the NDPs and TRIPS in the Bangladeshi pharmaceutical industry and then examined the prospects and challenges of the Bangladeshi pharmaceutical industry after graduation from LDC status.
References
M. Monirul Azam, “Globalizing Standard of Patent Protection in WTO Law and Policy Options for the LDCs: The Context of Bangladesh,” Chicago-Kent Journal of Intellectual Property, Volume 13, Issue 2, July, 2014, pp.402-488.
Reed Beall & Randall Kuhn, “Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis,” PLos Medicine, vol. 9, Jan. 2012, pp.1-9.
Mohammad M. Azam and Kristy Richardson, “Pharmaceutical Patent Protection and Trips Challenges for Bangladesh: An Appraisal of Bangladesh’s Patent Office and De-partment of Drug Administration,” Bond Law Review, Vol. 22, Issue 2, July 2011.
Md Shahiduzzaman Sarkar & Jagjit Kaur Plahe, “Accessing Affordable Medicines in a Post-TRIPS Environment: The Case of Bangladesh,” Journal of South Asian Studies, Vol. 44, No. 6, 2021, pp.1186-1205.
Mohammad Aktarul Alam Chowdhury, “Enforcement of Intellectual Property Rights in Bangladesh: to What Extent Is It TRIPS-Responsive?,” Beijing Law Review, Vol. 9 No. 3 Sept. 2018.
Mamun Ul Ala, “A firm-level analysis of the vulnerability of the Bangladeshi pharmaceutical industry to the TRIPS Agreement: Implications for R&D capability and technology transfer,” Procedia Economics and Finance, Vol. 5, 2013, pp.30-39.
Ravinder Rena, “Impact of WTO Policies on Developing Countries: Issues and Perspectives,” Transnational Corporations Review, Vol. 4, No. 3 Sept. 2012, pp.77-88.
Mazharul Islam, “LDC Graduation would stop enjoying the relaxations under the TRIPS agreement,” Academia Letters, July 2021, pp.1-4.
the United Nations Population Fund, (UNFPA) United Nations Fund of Population. https://bangladesh.unfpa.org/en/node/24314
Ganges–Brahmaputra Delta, Delta Alliance, http://www.delta-alliance.org/deltas/ganges-brahmaputra-delta
Bangladesh, Encyclopedia Britanica, Inc.
General information, Bangladesh, Foreign Ministry of Japan. ttps://www.mofa.go.jp/mofaj/area/bangladesh/index.html
“Bangladesh: 2021 Article IV Consultation-Press Release; Staff Report; and Statement by the Executive Director for Bangladesh, Country Report No. 2022/071,” March 7, 2022. https://www.imf.org/en/News/Articles/2022/03/03/pr2257-imf-executive-board-concludes-2021-article-iv-consultation-with-bangladesh
An Overview, Worldbank Bangladesh. https://www.worldbank.org/en/country/bangladesh/overview
Nadim Zawad Akil & Jeba Sabiha Tonny, “Not a good time for the RMG sector,” Dhaka Tribune, August 18th, 2020.
Major Economic Indicators of Bangladesh, Yearbook of Asian Affairs 2021, IDE JETRO, May 2021, P.8-9.
Arun Devnath, “IMF Forecasts Bangladesh Economy to Grow 6.6% in FY22,” Bloomberg, Dec. 19, 2021. https://www.bloomberg.com/news/articles/2021-12-19/imf-forecasts-bangladesh-economy-to-grow-6-6-next-fiscal-year
“World Bank projects 6.9 pct growth for Bangladesh in 2022-23,” Xinhua, Jan. 12, 2022, http://www.xinhuanet.com/english/asiapacific/20220112/d813443cec544506a8a48020e5e31b95/c.html
“ADB raises 2022 forecast for Bangladesh,” The Business Standard, December, 14, 2021, https://www.tbsnews.net/economy/adb-raises-2022-forecast-bangladesh-343459
Sudip Chaudhuri, “Evolution of the Pharmaceutical Industry in Bangladesh, 1982 to 2020,” Centre for Development Studies, Working Paper No. 495, July 2020, P.5.
Mayumi Murayama, 5th Ch.“Pharmaceuticals,” Bangladesh: An Unknown Indus-trial Country, Institute of Developing Economies, Japan External Trade Organization, 2014, p.179.
Sudip Chaudhuri, “Evolution of the Pharmaceutical Industry in Bangladesh, 1982 to 2020,” Centre for Development Studies, Working Paper No. 495, July 2020, P.8.
Mayumi Murayama, 5th Chapter “Pharmaceuticals,” Bangladesh: An Unknown Industrial Country, Institute of Developing Economies, Japan External Trade Organi-zation 2014, P.180.
“Report of the Expert Committee for Drugs on The National Drug Policy of Bangladesh 1982,” Directorate of Drug Administration, the Ministry of Health & Pop-ulation Control, Government of the Peoples’ Republic of Bangladesh, March 1986.
Mamun Rasid, “Pharmaceutical Sector of Bangladesh: Prospects and Challenges,” BRAC Business School, BRAC University Institutional Repository, 2014, P.12.
Sudip Chaudhuri, “Evolution of the Pharmaceutical Industry in Bangladesh, 1982 to 2020,” Centre for Development Studies, Working Paper No. 495, July 2020, P.12.
Yaeko Mitsumori, “An analysis on impact of TRIPS’ special exemption for LDC on Bangladesh pharmaceutical industry,” PICMET 2018, Aug. 19-23, 2018, Honolulu, HI, USA.
Notification for National Drug Policy 2005, Ministry of Health and Family Welfare, Public Health Section 1, April 18, 2005.
Fazlul Karim, “National Drug Policy 2005, Ministry of Health & Family Welfare, Public Health Section 1, Government of the People, April 18, 2005.
Pharmaceutical Market in Bangladesh 2013-2024. Bangladesh Ed., Basic Infor-mation on Healthcare Market in Newly Developing Countries, Medical Industry Inter-national Development Country Report, Ministry of Economy, Trade and Industry, March 2021, P.40.
Pharmaceutical Market in Bangladesh 2013-2024, Bangladesh Ed., Basic Infor-mation on Healthcare Market in Newly Developing Countries, Medical Industry Inter-national Development Country Report, Ministry of Economy, Trade and Industry, march 2021, P.42.
“Disease profile in Bangladesh,” Pharmaceutical Market in Bangladesh by Segment, Bangladesh Edition, Basic Information on Healthcare Market in Newly Developing Countries, Medical Industry International Development Country Report, Ministry of Economy, Trade and Industry, March 2021, P.17.
Pharmaceutical Industry of Bangladesh, the multi-billion Dollar Industry, EBL Securities Ltd., P9.
National STEPS Survey for Non-communicable Diseases Risk Factors in Bangla-desh 2018, National Institute of Preventive and Social Medicine (NIPSOM), Mohakhali, Dhaka 1212, The Ministry of Health and Family Welfare, Bangladesh Government, World Health Organization, Feb. 2018.
Nadeem Rizwan and Sanjay Kathuria, “The Pharmaceutical Sector in Bangladesh,” Attracting Investment in Bangladesh – Sectoral Analyses, A Diagnostic Trade Integration Study, World Bank Group, Nov. 2016, pp.193-207.
Padmashree Gehl Sampath, “Pharmaceutical Manufacturing in Bangladesh – A Success Story. What can we learn? FEAPM Advocacy Series No. 1, Federation of East African Pharmaceutical Manufacturers (FEAPM), May 2019, P.15.
Padmashree Gehl Sampath, “Pharmaceutical Manufacturing in Bangladesh – A Success Story. What can we learn? FEAPM Advocacy Series No. 1, Federation of East African Pharmaceutical Manufacturers (FEAPM), May 2019, P.13.
Market Share of Top 10 Player, Pharmaceutical Industry of Bangladesh, The multi-billion Dollar Industry, EBL Securities Ltd., P.14.
Developing National Intellectual Property Policy for Bangladesh, An Assessment of National Intellectual System, World Intellectual Property Organization (WIPO), Oct. 2013, P.3.
Sudip Chaudhuri, “Evolution of the Pharmaceutical Industry in Bangladesh, 1982 to 2020,” Centre for Development Studies, Working Paper No. 495, July 2020, P.5-6.
Mohammad Towhidul Islam, “Pharmaceutical mailbox patents and LDC graduation,” The Financial Express, May 29, 2021, P.1.
Developing National Intellectual Property Policy for Bangladesh - An Assessment of National Intellectual Property System, World Intellectual Property Organization (WIPO), Oct. 2013, P.8.
Patent Applied and Granted data in Bangladesh, DPDT website.
WTO members agree to extend drug patent exemption for poorest members, WTO 2015 news Items, Nov. 6, 2015.
Padmashree Gehl Sampath, “Pharmaceutical Manufacturing in Bangladesh – A success Story. What can we learn?” Federation of East African Pharmaceutical Manu-facturers (FEAPM) Advocacy Series No. 1, May 2019, P.15.
Pharmaceutical Industry of Bangladesh, the multi-billion Dollar Industry, EBL Securities Ltd., July 2019, P.11.
Bangladesh is scheduled to graduate in 2026, LDC Portal, International Support Measures for LDCs, Feb. 28, 2022. https://www.un.org/ldcportal/content/bangladesh-graduation-status
“Graduation of Bangladesh, the Lao People’s Democratic Republic and Nepal from the least developed country category,” Report of the Economic and Social Council, United Nations General Assembly, Nov. 11, 2021.
“Bangladesh Preparing for Sustainable Graduation,” Annual Monitoring Report 2021 submitted to UN-CDP, Economic Relations Division, Ministry of Finance, Gov-ernment of the People’s Republic of Bangladesh, November 2021.
“Monitoring of countries graduating and graduated from the list of LDC category: Bangladesh,” Committee for Development Policy 24th Plenary Session, United Nations Feb. 21-25, 2022 Virtual meeting, Committee for Development Policy, United Nations.
“Booming Bangladesh sets off to graduate leaving the LDC category,” The Business Standard, Dec. 26, 2021. https://www.tbsnews.net/economy/booming-bangladesh-sets-graduate-leaving-ldc-category-349024
“Graduation of Bangladesh, Lao People’s Democratic Republic and Nepal from the LDC category, Department of Economic and Social Affairs, United Nations, Nov 24, 2021.
Hussain Shazzad, “Managing Bangladesh’s LDC Graduation: Daunting or Doable?,” Opinion, The Daily Star, Dec. 15, 2021. https://www.thedailystar.net/views/opinion/news/managing-bangladeshs-ldc-graduation-daunting-or-doable-2917816
Ibrahim Hossain Ovi, “LDC graduation: New opportunities, new challenges,” Dhaka Tribune, Feb. 27. 2021.
Jesmin Sultana, “Future Prospects and Barriers of Pharmaceutical Industries in Bangladesh,” Bangladesh Pharmaceutical Journal, Vol.19 No.1, 2016, pp.53-57.
Monirul Azam, Ch. II “Case Study on Bangladesh’s Pharmaceutical Industry, Leg-islative and Institutional Framework and Pricing of Pharmaceuticals,” Intellectual Property and Public Health in Developing World, Open Book Publisher, P.58.
Sudip Chaudhuri, “Evolution of the Pharmaceutical Industry in Bangladesh, 1982 to 2020,” Centre for Development Studies, Working Paper No. 495, July 2020, P.4.
Yaeko Mitsumori, “A study on IPR Policies and Implementation in Bangladesh,” The 34th Annual Academic Conference of the Japan Society for Research Policy and Inno-vation Management, at GRIPS, Oct. 23, 2019, pp.378-381.
